Shikonin Binds and Represses PPARγ Activity by Releasing Coactivators and Modulating Histone Methylation Codes.
Ui-Hyun ParkHyeSook YounEun-Joo KimSoo-Jong UmPublished in: Nutrients (2023)
Shikonin, a natural ingredient produced by Lithospermum erythrorhizon , has anti-inflammatory, anti-cancer, and anti-obesity effects. It also inhibits adipocyte differentiation; however, the underlying molecular and epigenetic mechanisms remain unclear. We performed RNA-sequencing of shikonin-treated 3T3-L1 cells. Gene ontology and gene set enrichment analysis showed that shikonin is significantly associated with genes related to adipogenesis, histone modification, and PPARγ. Shikonin treatment downregulated the mRNA expression of PPARγ-responsive genes and rosiglitazone-induced transcriptional activity of PPARγ. Microscale thermophoresis assays showed a K D value 1.4 ± 0.13 μM for binding between shikonin and PPARγ. Glutathione S-transferase pull-down assays exhibited that shikonin blocked the rosiglitazone-dependent association of PPARγ with its coactivator CBP. In addition, shikonin decreased the enrichment of the active histone code H3K4me3 and increased the repressive code H3K27me3 of PPARγ target promoters. Shikonin is a PPARγ antagonist that suppresses adipogenesis by regulating the enrichment of histone codes during adipogenesis. Therefore, it may be used to treat obesity-related disorders via epigenetic changes.
Keyphrases
- insulin resistance
- dna methylation
- high fat diet induced
- genome wide
- metabolic syndrome
- fatty acid
- gene expression
- adipose tissue
- skeletal muscle
- type diabetes
- genome wide identification
- induced apoptosis
- anti inflammatory
- weight loss
- signaling pathway
- oxidative stress
- cell proliferation
- drug induced
- cell cycle arrest
- newly diagnosed
- endoplasmic reticulum stress
- diabetic rats
- high glucose
- drug delivery
- endothelial cells
- cancer therapy
- heat shock protein